Duality Biotherapeutics, Inc. (HKG:9606)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
406.40
+3.60 (0.89%)
Sep 9, 2025, 4:08 PM HKT
0.89%
Market Cap35.78B
Revenue (ttm)2.38B
Net Income (ttm)-3.10B
Shares Out88.04M
EPS (ttm)-124.82
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume917,200
Average Volume616,001
Open410.40
Previous Close402.80
Day's Range405.00 - 433.00
52-Week Range165.50 - 433.80
Betan/a
RSI65.01
Earnings DateAug 26, 2025

About Duality Biotherapeutics

Duality Biotherapeutics, Inc., a clinical-stage biotech company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others. The company provides DB-1303/BNT323, a HER2 ADC candidate targeting cancers, including endometrial cancer1 and breast cancer2; DB-1311/BNT324, a B7-H3 ADC candidate targeting cancers, such as small-cell lung cancer3, castration-resistant prostate cancer4, esophageal squamous cell carcinoma5, and head and neck squamous cell carcinoma; and other clinical-stage ADCs. It... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2019
Employees 170
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 9606
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.